Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Nov 15: Patients with ROS1-positive non-small cell lung cancer have a new treatment option after the FDA approved Bristol Myers Squibbs Augtyro (repotrectinib) on Wednesday
doi:10.1007/s00441-019-03016-8 [2] Deek SA
Part of the bigger inside-out picture
I couldn't walk, and Dr
Peer review involves independent experts evaluating methodology, data analysis, and conclusions before publication
US$ 22.46
.jpg)
US$ 23.45
US$ 23.48
US$ 23.91
US$ 21.63
US$ 20.48
US$ 24.54
US$ 24.55
